Medtronic plc manufactures and sells device-based medical therapies worldwide. The companys Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The companys Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.
FINANCIAL RATIOS of Medtronic (MDT)
Valuation Ratios |
|
| P/E Ratio | 0 |
| Price to Sales | 0 |
| Price to Book | 0 |
| Price to Tangible Book | |
| Price to Cash Flow | 0 |
| Price to Free Cash Flow | 0 |
Growth Rates |
|
| Sales Growth Rate | -100% |
| Sales - 3 Yr. Growth Rate | % |
| EPS Growth Rate | % |
| EPS - 3 Yr. Growth Rate | % |
| Capital Spending Gr. Rate | NaN% |
| Cap. Spend. - 3 Yr. Gr. Rate | NaN% |
Financial Strength |
|
| Quick Ratio | NaN |
| Current Ratio | NaN |
| LT Debt to Equity | 0% |
| Total Debt to Equity | 0% |
| Interest Coverage | 0 |
Management Effectiveness |
|
| Return On Assets | 0% |
| Ret/ On Assets - 3 Yr. Avg. | 0% |
| Return On Total Capital | 0% |
| Ret/ On T. Cap. - 3 Yr. Avg. | 0% |
| Return On Equity | 0% |
| Return On Equity - 3 Yr. Avg. | 0% |
| Asset Turnover | 0 |
Profitability Ratios |
|
| Gross Margin | 0% |
| Gross Margin - 3 Yr. Avg. | 0% |
| EBITDA Margin | 0% |
| EBITDA Margin - 3 Yr. Avg. | 0% |
| Operating Margin | 0% |
| Oper. Margin - 3 Yr. Avg. | 0% |
| Pre-Tax Margin | 0% |
| Pre-Tax Margin - 3 Yr. Avg. | 0% |
| Net Profit Margin | 0% |
| Net Profit Margin - 3 Yr. Avg. | 0% |
| Effective Tax Rate | 0% |
| Eff/ Tax Rate - 3 Yr. Avg. | 0% |
| Payout Ratio | 0% |
MDT stock valuation input parameters
Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDT stock intrinsic value calculation we used $29953 million for the last fiscal year's total revenue generated by Medtronic. The default revenue input number comes from 0001 income statement of Medtronic. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.
Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
We use three input parameters to forecast the revenue growth rate in our MDT stock valuation model: a) initial revenue growth rate of 2.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.
Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
The initial discount rate of 4.9%, whose default value for MDT is calculated based on our internal credit rating of Medtronic, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Medtronic.
By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.
Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDT stock the variable cost ratio is equal to 82.1%.
Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDT stock. These expenses increase with the level of inflation in subsequent years.
Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Medtronic.
Corporate tax rate of 27% is the nominal tax rate for Medtronic. In reality, companies find ways to pay much less taxes than that or not to pay them at all.
Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDT stock is equal to 0%.
Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDT are equal to 117.8%.
Life of production assets of 25 years is the average useful life of capital assets used in Medtronic operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.
Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDT is equal to 12.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.
Book value of equity - $50720 million for Medtronic - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.
Shares outstanding of 1351.71 million for Medtronic is needed to calculate the intrinsic value of one share.
Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Medtronic at the current share price and the inputted number of shares is $117.6 billion.